Imricor Announces First Sales Collaboration With Philips
2020年8月4日 - 9:00PM
ビジネスワイヤ(英語)
Imricor Medical Systems, Inc. (Company or
Imricor) (ASX:IMR) the worldwide leader in MRI-guided
cardiac ablation products, is pleased to announce the first sales
collaboration with Philips, a global leader in healthcare
technology.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200804005317/en/
Imricor announces first sales partnership
with Philips. (Photo: Business Wire)
The sales collaboration provides Philips non-exclusive rights to
re-sell Imricor’s Advantage-MR System, along with Philips’
industry-leading MRI scanners in European countries that recognize
the CE mark. This agreement is the first such agreement signed by
Imricor.
Imricor’s Chair and CEO, Steve Wedan said: “This agreement is a
major milestone for Imricor, allowing Philips to take the lead on
driving iCMR lab adoption and enabling us to focus on supporting
utilization, growing our portfolio of consumable devices and
expanding our indications for use. In this way, we each leverage
our strengths as we work together to deliver a new standard of care
in the treatment of cardiac arrhythmias.”
The Imricor products are specifically designed to enable cardiac
ablations under real-time MRI guidance. Imricor is the first and
only company to offer a fully MR conditional EP recorder/stimulator
system and cardiac ablation catheters for use in the MRI
environment.
“Treatment procedures guided by MR represent an emerging field
that extends the value of MR and complements established
X-ray-based image-guided therapy systems,” said Arjen Radder,
General Manager MR Business at Philips. “By working with Imricor we
can support healthcare providers to offer MRI-guided cardiac
ablation procedures for their patients.”
This collaboration is the latest achievement in the partnership
between Imricor and Philips, which began in 2010.
“We are very proud to have a sales partnership with a company
like Philips. We look forward to working with the talented Philips
sales teams to leverage the extensive and outstanding relationships
they have with customers, to help build new iCMR suites, and to
identify potential customers that already have access to 1.5T
compatible MRI systems.” Greg Englehardt, Director of Sales at
Imricor.
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for
more information about Imricor, Foreign Ownership Restrictions, and
Forward-Looking Statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200804005317/en/
Investors: Steve Wedan Executive Chair, President and CEO
Email: steve.wedan@imricor.com Carrie Barrack Senior Advisor, Cato
& Clive Email: carrie@catoandclive.com Phone: +61 422 464 028
Rest of World Media: Nick Twohy Director of Marketing,
Imricor Email: nick.twohy@imricor.com Phone: +1 952 818 8407
Australia Media: Carrie Barrack Senior Advisor, Cato &
Clive Email: carrie@catoandclive.com Mobile: +61 422 464 028
iMetal Resources (TSXV:IMR)
過去 株価チャート
から 12 2024 まで 1 2025
iMetal Resources (TSXV:IMR)
過去 株価チャート
から 1 2024 まで 1 2025